These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 15292283)

  • 41. Effects of radiation on the thyroid gland.
    Van Middlesworth L
    Adv Intern Med; 1989; 34():265-84. PubMed ID: 2644760
    [No Abstract]   [Full Text] [Related]  

  • 42. [Metabolic radiotherapy in differentiated carcinoma of the thyroid].
    Serena A; Richter JA; Charvet MA; Honorato J
    Rev Med Univ Navarra; 1984 Dec; 28(4):35-9. PubMed ID: 6441993
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radio-active iodine in the treatment of cancer of the thyroid.
    Lahneche B
    Ann Radiol (Paris); 1977; 20(8):779-82. PubMed ID: 610549
    [No Abstract]   [Full Text] [Related]  

  • 45. Iodine-refractory differentiated thyroid cancer: an ominous diagnosis with the potential for a brighter future.
    Sipos JA; Kloos RT
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):767-9. PubMed ID: 18997668
    [No Abstract]   [Full Text] [Related]  

  • 46. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients.
    Tala Jury HP; Castagna MG; Fioravanti C; Cipri C; Brianzoni E; Pacini F
    J Clin Endocrinol Metab; 2010 Jan; 95(1):230-7. PubMed ID: 19858316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Simultaneous papillary carcinoma in a thyroglossal duct remnant and the thyroid gland].
    Lehnerdt KH; Mehlhorn J; Nürnberger H; Deitmer T
    Laryngorhinootologie; 2006 Dec; 85(12):909-12. PubMed ID: 16586292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
    Hay ID; Kaggal S; Thompson GB
    Eur Thyroid J; 2022 Aug; 11(4):. PubMed ID: 35713242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radioiodine - the success story of Nuclear Medicine : 75th Anniversary of the first use of Iodine-131 in humans.
    McCready VR
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):179-182. PubMed ID: 27761621
    [No Abstract]   [Full Text] [Related]  

  • 50. Radioiodine Remnant Ablation: A Critical Review.
    Bal CS; Padhy AK
    World J Nucl Med; 2015; 14(3):144-55. PubMed ID: 26420983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.
    Ain KB
    Endocrine; 2015 Sep; 50(1):61-6. PubMed ID: 26109472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique.
    Roos DE; Smith JG
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):493-5. PubMed ID: 10348276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized trial of remnant ablation--in search of an impossible dream?
    Mazzaferri E
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3662-4. PubMed ID: 15292283
    [No Abstract]   [Full Text] [Related]  

  • 54. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation.
    Haugen BR
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3665-7. PubMed ID: 15292284
    [No Abstract]   [Full Text] [Related]  

  • 55. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
    Doi SA; Woodhouse NJ
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.